Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/18 | 05/18 | 118,235 sh2 trades | $27.19avg. | $3,214,999.73 | −7.8% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/07–05/11 | 05/11 | 68,491 sh9 trades | $28.47avg. | $1,949,634.12 | −4.3% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/11 | 05/11 | 13,917 sh4 trades | $30.13avg. | $419,263.08 | −7.9% | |
James Woodruff LillieChief Scientific Officer | MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/07 | 05/11 | 721 sh | $28.28 | $20,389.88 | −0.3% |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/07 | 05/11 | 4,438 sh2 trades | $28.54avg. | $126,639.62 | −1.3% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/04–05/06 | 05/06 | 49,744 sh8 trades | $28.39avg. | $1,412,235.5 | −3.1% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/04–05/06 | 05/06 | 51,707 sh8 trades | $28.40avg. | $1,468,251.39 | −17.5% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/04–05/06 | 05/06 | 50,280 sh8 trades | $28.39avg. | $1,427,594.4 | −12.5% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/04–05/06 | 05/06 | 36,371 sh8 trades | $28.17avg. | $1,024,719.24 | −9.3% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 05/04 | 05/06 | 13,917 sh4 trades | $27.89avg. | $388,176.72 | −7.3% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 04/27–04/28 | 04/29 | 69,835 sh5 trades | $29.89avg. | $2,087,687.49 | −27.8% | |
MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 04/27 | 04/29 | 45,422 sh3 trades | $29.66avg. | $1,347,066.31 | −17.7% | |
MapLight TherapeuticsMPLT | Open-market sale | 04/15–04/16 | 04/17 | 19,187 sh3 trades | $27.16avg. | $521,146.07 | −1.2% | |
MapLight TherapeuticsMPLT | Open-market sale | 04/15–04/16 | 04/17 | 4,513 sh3 trades | $27.16avg. | $122,573.99 | −1.5% | |
MapLight TherapeuticsMPLT | Open-market sale | 04/15–04/16 | 04/17 | 1,827 sh3 trades | $26.89avg. | $49,134.18 | −1.0% | |
MapLight TherapeuticsMPLT | Open-market sale | 04/15–04/16 | 04/17 | 3,213 sh3 trades | $27.03avg. | $86,858.53 | −0.8% | |
MapLight TherapeuticsMPLT | Open-market sale | 04/15–04/16 | 04/17 | 2,922 sh3 trades | $26.89avg. | $78,572.14 | −0.7% | |
Jonathan GillisCAAO and PAO | MapLight TherapeuticsMPLT | Open-market sale | 04/15 | 04/17 | 3,590 sh | $26.61 | $95,529.9 | −1.4% |
Robert C. MalenkaDirector | MapLight TherapeuticsMPLT | Open-market sale10b5-1 plan | 04/15 | 04/17 | 8,593 sh | $26.90 | $231,151.7 | −2.6% |
Anatol KreitzerChief Discovery Officer | MapLight TherapeuticsMPLT | Open-market sale | 04/15 | 04/17 | 3,316 sh | $26.61 | $88,238.76 | −1.3% |